Articles from Rockwell Medical, Inc.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced a product purchase agreement with the leading at-home and acute care dialysis provider in the United States (the "Customer"). Under the terms of the agreement, Rockwell Medical will supply the Customer with the Company's liquid acid RenalPure® and liquid bicarbonate SteriLyte®, both of which will be packaged in either the Company's four-per-case packaging for larger dialysis settings or two-per-case packaging for smaller acute care and at-home care settings.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company executed a distribution agreement with Nipro Medical Corporation ("Nipro"), as part of Nipro Corporation Japan, a leader in the global healthcare and medical device industry.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and six months ended June 30, 2024.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it has launched a Convenience Pack, which includes two 1-gallon pre-mixed containers of one of the Company's hemodialysis concentrate products CitraPure®, RenalPure®, or SteriLyte®, offering a number of advantages for home patients and acute facilities.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, announced that the Company's President and Chief Executive Officer, Dr. Mark Strobeck, will present at the H.C. Wainwright 3rd Annual Kidney Conference, which is being held today virtually. For more information, visit hcwevents.com/kidneyconference.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Tim Chole was promoted to Chief Commercial Officer, reporting to the Company's President and CEO, Dr. Mark Strobeck.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2024.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it entered into a product purchase agreement with one of the largest health systems in the Mountain West region of the United States. Under the terms of the agreement, Rockwell Medical will supply this health system with the Company's liquid and dry acid and bicarbonate hemodialysis concentrates, cleaning agents, hemodialysis concentrates mixers and any additional products offered by Rockwell Medical.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2024 on Tuesday, May 14, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it entered into a new and expanded distribution agreement with BioNuclear and Atlantic Medical International ("AMI"), respectively. In the aggregate, these agreements are expected to generate approximately $1 million in annual revenues for the Company.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it has been certified as a Great Place to Work® for the second year in a row.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months and twelve months ended December 31, 2023.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2023 on Thursday, March 21, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company amended its loan and security agreement with Innovatus Life Sciences Lending Fund I, LP ("Innovatus").

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended September 30, 2023.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Jesse Neri has joined the Company as Senior Vice President, Finance. Mr. Neri will oversee all aspects of Rockwell Medical's finance organization.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the third quarter ended September 30, 2023 on Tuesday, November 14, 2023. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company entered into a three-year product purchase agreement with Centers for Dialysis Care, Inc. ("CDC"), the largest non-profit, independent outpatient dialysis provider in Northeast Ohio.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company entered into a three-year product purchase agreement with Sanderling Renal Services, Inc. ("Sanderling"), a full-service provider of in-center, home dialysis and renal telemedicine services focusing on patients in rural and underserved communities across the United States.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company entered into an amended and restated products purchase agreement with its largest customer (the "Customer").

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company's President and CEO, Dr. Mark Strobeck, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 11:00 am ET at the Lotte New York Palace Hotel. More information about the conference is available at hcwevents.com/annualconference.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial results and business updates for the three and six months ended June 30, 2023.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of stock options to purchase an aggregate of 30,000 shares of the Company’s common stock to 11 new employees (the “Inducement Grants”) on May 10, 2023 (the “Grant Date”). The Inducement Grants have been granted outside of the Company’s 2018 Long Term Incentive Plan (“Plan”) but remain subject to the terms and conditions of such Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Rockwell Medical in accordance with Nasdaq Listing Rule 5635(c)(4).

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2023 on Monday, August 14, 2023. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company acquired the hemodialysis concentrates business from Evoqua Water Technologies ("Evoqua") for $11 million up front in cash plus two milestone payments of $2.5 million each at 12- and 24-months from the closing of the transaction. Rockwell Medical purchased this business through its cash balance. At closing of the transaction, Rockwell Medical had approximately $15.3 million in cash and cash equivalents.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company entered into a three-year co-promotion services agreement with B. Braun Medical Inc. ("B. Braun"), a leader in renal therapies including innovative, high-quality products for hemodialysis.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company was added to the Russell Microcap® Index.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2023.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company expanded its geographic footprint by entering a long-term supply agreement with Global Medical Supply Chain LLC to begin selling Rockwell's hemodialysis concentrates products into the United Arab Emirates.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that its international partner, Drogsan Pharmaceuticals, submitted a Marketing Authorization application and GMP application for Triferic® AVNU to the Turkish Medicines and Medical Devices Agency ("TMMDA"), for which Drogsan received priority status and high priority status, respectively.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2023 on Monday, May 15, 2023. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, announced that the Company is exhibiting its hemodialysis concentrates portfolio in Booth #503 at the National Kidney Foundation Spring Clinical Meetings, which will be held April 11-15, 2023 at the Austin Convention Center in Austin, Texas.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months and full-year ended December 31, 2022.

Rockwell Medical, Inc. ("the Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, announced that it will showcase its hemodialysis concentrates portfolio at DialysisTechConneXion40 ("DTX40"). Hosted by the National Association of Nephrology Technicians/Technologists, DTX40 will be held at the Tropicana Hotel in Las Vegas, Nevada from March 28-31, 2023.

Rockwell Medical, Inc. ("the Company) (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, announced that it has been certified as a Great Place to Work® in 2023, the Company's inaugural year participating in the accreditation.

Rockwell Medical, Inc. (Nasdaq:RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2022 on Thursday, March 30, 2023. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, announced that the Company signed a three-year product purchase agreement with Concerto Renal Services ("Concerto"), the largest provider of dialysis in skilled nursing facilities in the United States. Under the terms of the agreement, Rockwell Medical will be the primary supplier of liquid and dry acid and bicarbonate concentrates to Concerto through a three-year commitment that includes supply and purchasing minimums. Concerto operates in eleven states — Illinois, Maryland, Kansas, Missouri, Indiana, Michigan, Ohio, Wisconsin, Georgia, Pennsylvania, and Delaware — and is launching operations in several additional states.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, announced that the Company signed a three-year, multi-million dollar per annum product purchase agreement with the largest non-profit dialysis provider in the United States. As part of the agreement, Rockwell Medical will be the preferred supplier of liquid and dry acid and bicarbonate concentrates to this non-profit dialysis provider's hemodialysis facilities located throughout the United States.

Rockwell Medical, Inc. (“Rockwell” or the “Company”) (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, announced that the Company is adding new business within the Minnesota region. Rockwell started to supply these clinics with its hemodialysis concentrates products effective December 5, 2022, anticipates that all clinics will be onboarded by January 1, 2023, and expects to generate over one million dollars in revenue the first year.

Rockwell Medical, Inc. (“Rockwell” or the “Company”) (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today provided an update on its overall business strategy and announced its financial and operational results for the third quarter ended September 30, 2022.

Rockwell Medical, Inc. (“Rockwell” or the “Company”) (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, announced that the Company is reacquiring its distribution rights to its hemodialysis concentrates products from Baxter and has agreed to terminate the exclusive distribution agreement dated October 2, 2014. Exclusivity and other provisions associated with the distribution agreement terminate November 9, 2022 and the remaining operational elements of the agreement terminate December 31, 2022.

Rockwell Medical, Inc. (Nasdaq:RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today announced that it will release its financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET.

Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of stock options to purchase an aggregate of 66,000 shares of the Company’s common stock to three new employees (the “Inducement Grants”) on September 9, 2022 (the “Grant Date”). The Inducement Grants have been granted outside of the Company’s 2018 Long Term Incentive Plan (“Plan”) but remain subject to the terms and conditions of such Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Rockwell Medical in accordance with Nasdaq Listing Rule 5635(c)(4).

Rockwell Medical, Inc. (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today announced that Heather Hunter has joined the Company as SVP, Chief Corporate Affairs Officer. In this role, Heather will be responsible for the Company’s investor relations, media relations, government affairs, patient advocacy, communications, and branding.

Rockwell Medical, Inc. (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today announced its financial and operational results for the second quarter ended June 30, 2022.